Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial.

BOSTON, March 28, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several updates on the Company’s type 1 diabetes (T1D) portfolio. The economy has been on shaky ground ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

In this Tools of the Trade article, Jordan Lee describes the development and use of the Tumor Molecular Pathology (TMP) toolkit, a cancer subtyping tool that can assign TCGA molecular subtypes to ...

Tunnelling teams working on the Coffs Harbour bypass have hit another major milestone after breaking through what will be the second largest of three tunnels being built for the project. The ...

Two quantum registers, the first marking whether a point is an outlier and the second to store the seed number – which is also the cluster number – are added to the quantum database.